Jo-Anne Young, MD

Professor of Medicine, Division of Infectious Diseases and International Medicine

Jo-Anne Young

Contact Info

Mailing Address:
420 Delaware Street SE
MMC 250, Room D416 Mayo
Memorial Building
Minneapolis, MN 55455

Administrative Assistant Name
IDIM Admin

Administrative Phone

Administrative Email

Administrative Fax Number

Professor of Medicine, Division of Infectious Diseases and International Medicine

Transplant, Viral and Fungal Infection

Medical School, Case Western Reserve University School of Medicine, Cleveland, OH

Residency, Vanderbilt University Medical Center, Nashville, TN

Fellowship, University of Washington, Seattle, WA

Bachelor's Degree, Case Western Reserve University, Western Reserve College, Cleveland, Ohio


Jo-Anne Young (née van Burik), M.D., is a Professor of Medicine and Medical Director of the Program in Adult Transplant Infectious Disease. She joined the faculty in 1999. She received both her B.A. and M.D. from Case Western Reserve University and completed a residency in Medicine at Vanderbilt University Medical Center. Her fellowship in Infectious Disease and several years of junior faculty service were at the University of Washington with the Fred Hutchinson Cancer Research Center. Dr. Young’s primary area of interest is bringing diagnostic and treatment opportunities to the bedside for transplant patients. She has worked on developing diagnostic testing for complicated fungal infections of the immunocompromised host. Currently, Dr. Young is lead investigator at the University of Minnesota for multiple clinical trials on bacterial, viral, and fungal agents, as well as vaccines, for transplant patients.


  • Immunocompromised patients
  • Mycology
  • Herpes Virology

Awards & Recognition

  • Minnesota Monthly "Best Doctor" (2014)
  • Minnesota Monthly Best Doctors for Women, 2014
  • Named to Best Doctors in America  (2009, 2013)
  • Graduated magna cum laude; major Chemistry, minor Biochemistry for her BA from Case Western Reserve College, Cleveland, Ohio.

Professional Associations



  • Khoruts A, Hippen KL, Lemire AM, Holtan SG, Knights D, Young JH. (2017) Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota. Translational Research. 2017 Jan;179:116-125.
  • Gea-Banacloche J, Komanduri KV, Carpenter P, Paczesny S, Sarantopoulos S, Young JA, El Kassar N, Le RQ, Schultz KR, Griffith LM, Savani BN, Wingard JR. (2016) National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. Biology of Blood and Marrow Transplant Oct 14. pii: S1083-8791(16)30391-3.
  • Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JH, Bennett JE. (2016) Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Disease 63(4):433-42 (executive summary) and e1-e60.
  • Ballen K, Woo Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M, Antin J, Bhatt AS, Boeckh M, Chen G, Dandoy C, George B, Laughlin MJ, Lazarus HM, MacMillan ML, Margolis DA, Marks DI, Norkin M, Rosenthal J, Saad A, Savani B, Schouten HC, Storek J, Szabolcs P, Ustun C, Verneris MR, Waller EK, Weisdorf DJ, Williams KM, Wingard JR, Wirk B, Wolfs T, Young JH, Auletta J, Komanduri KV, Lindemans C, Riches ML. (2016) Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplant 22(9):1636-45.
  • Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, Alangaden GJ, Brown JM, Fredricks DN Heinz WJ, Herbrecht R, Klimko N, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Racil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruatanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, and Vehreschild MJ; VITAL and FungiScope Mucormycosis Investigators. (2016) Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infectious Disease 16(7):828-37.
  • Beaird OE, Freifeld A, Ison MG, Lawrence SJ, Theodoropoulos N, Clark NM, Razonable RR, Alangaden G, Miller R, Smith J, Young JA, Hawkinson D, Pursell K, Kaul DR. (2016) Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transplant Infectious Disease 18(2):210-5.
  • Riches ML, Trifilio S, Chen M, Ahn KW, Langston A, Lazarus HM, Marks DI, Martino R, Maziarz RT, Papanicolaou GA, Wingard JR, Young JA, Bennett CL. (2016) Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: A CIBMTR Infection & Immune Reconstitution analysis. Bone Marrow Transplantation 51(2):277-82. Corrigendum 51(3):322.
  • Young JAH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JW, Langston AA, Schuster MG, Kaul DR, Martin SI, Anasetti C, for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0201. (2016) Infections following transplantation of bone marrow or peripheral-blood stem cells from unrelated donors. Biology of Blood and Marrow Transplant 22(2):359-70.
  • Price TH, Boeckh M, Harrison RW, McCullough J, Ness PM, Strauss RG, Nichols WG, Hamza TH, Cushing MM, King KE, Young JA, Williams E, McFarland J, Holter Chakrabarty J, Sloan SR, Friedman D, Parekh S, Sachais BS, Kiss JE, Assmann SF. (2015) Efficacy of transfusion of granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood 126(18):2153-61.
  • Lunde LE, Dasaraju S, Cao Q, Cohn CS, Reding M, Bejanyan N, Trottier B, Rogosheske J, Brunstein C, Warlick E, Young JA, Weisdorf DJ, Ustun C. (2015) Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplantation 50(11):1432-7.
  • MacMillan ML, DeFor TE, Young JAH, Dusenbery KE, Blazar BR, Slungaard A, Zierhut H, Weisdorf DJ, Wagner JE. (2015) Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood 125(24):3798-804.
  • Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolasou GA, Shea TC, Mossad SB, Andreadis C, Young JA, Buadi FK, El Idrissi M, Heineman TC, Berkowitz EM. (2014) A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 124(19):2921-9.
  • Assi M, Martin S, Wheat LJ, Hage C, Freifeld A, Avery R, Baddley JW, Vergidis P, Miller R, Andes D, Young JA, Hammoud K, Huprikar S, McKinsey D, Myint T, Garcia-Diaz J, Esguerra E, Kwak EJ, Morris M, Mullane KM, Prakash V, Burdette SD, Sandid M, Dickter J, Ostrander D, Antoun SA, Kaul DR. (2013) Histoplasmosis after Solid Organ Transplant. Clinical Infectious Disease 57(11):1542-9
  • Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MA. (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Recommendations of the Center for International Blood and Marrow Transplant Research (CIBMTR®), the National Marrow Donor Program (NMDP), the European Blood and Marrow Transplant Group (EBMT), the American Society of Blood and Marrow Transplantation (ASBMT), the Canadian Blood and Marrow Transplant Group (CBMTG), the Infectious Disease Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the Association of Medical Microbiology and Infectious Diseases Canada (AMMI), and the Centers for Disease Control and Prevention (CDC). Biology of Blood and Marrow Transplantation 15(10):1143-238.
  • Infections in recipients of hematopoietic stem cell transplantation. In Mandell GL, Bennett JE, Dolin R (eds.) Principles and Practice of Infectious Diseases. Elsevier Science, Churchill Livingstone.
    • Young JA, Weisdorf DJ. (2014) Chapter 310, 8th edition, 3425-3439.
    • Young JA, Weisdorf DJ. (2009) Chapter 311, 7th edition, 3821-3837.
    • Van Burik JA, Weisdorf DJ. (2004) Chapter 311, 6th edition, 3486-3500.
    • Van Burik JA, Weisdorf DJ. (1999) Chapter 303, 5th edition, 3136-3147.
  • Casadevall A, Bertuzzi S, Buchmeier MJ, Davis RJ, Drake H, Fang FC, Gilbert J, Goldman BM, Imperiale MJ, Matsumura P, McAdam AJ, Pasetti MF, Sandri-Goldin RM, Silhavy T, Rice L, Young JAH, Shenk T. (2016) ASM Journals Eliminate Impact Factor Information from Journal Websites.
    • Clin Microbiol Rev. 2016 Oct;29(4):i-ii.
  • Karras NA, Weeres M, Sessions W, Xu X, Defor T, Young JA, Stefanski H, Brunstein C, Cooley S, Miller JS, Blazar BR, Wagner JE, Verneris MR. (2013) A randomized trial of one vs. two doses of influenza vaccine following allogeneic transplantation. Biology of Blood and Marrow Transplantation 19(1):109-16.
  • Bock AM, Cao Q, Ferrieri P, Young JA, Weisdorf DJ. (2013) Bacteremia in blood or marrow transplant patients: clinical risk factors for infection and emerging antibiotic resistance. Biology of Blood and Marrow Transplantation 19(1):102-8.
  • Vydra J, Shanley RM, George I, Ustun C, Smith AR, Weisdorf DJ, Young JA. (2012) Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clinical Infectious Disease 55(6):764-70.
  • Ustun C, Slabý J, Shanley RM, Vydra J, Smith AR, Wagner JE, Weisdorf DJ, Young JA. (2012) Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time. Biology of Blood and Marrow Transplantation 19(10):1580-8.
  • Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young J-AH, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M. (2011) Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infectious Disease 11(4):284-292. Erratum 11(5):343.
  • Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young J-AH, Wingard JR. (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Disease 52(4):e56-93; 427-431.
  • Tomblyn M, Young J-AH, Haagenson MD, Klein JP, Trachtenberg EA, Storek J, Spellman SR, Cooley S, Miller JS, Weisdorf DJ. (2010) Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biology of Blood and Marrow Transplantation 16(8):1155-61.
  • Blaes AH, Cao Q, Wagner JE, Young J-AH, Weisdorf DJ, Brusntein CG. (2010) Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after anti-thymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biology of Blood and Marrow Transplantation 16(2):287-91.
  • Beck JC, Wagner JE, Defor TE, Brunstein CG, Schleiss MR, Young JA, Weisdorf DH, Cooley S, Miller JS, Verneris MR. (2010) Impact of cytomegalovirus reactivation after umbilical cord blood transplantation. Biology of Blood and Marrow Transplantation 16(2):215-22. 



  • Infectious Disease


Delaware Street Clinic (Infectious Disease/HIV Clinic)

Board Certifications

Infectious Diseases

Clinical Interests

Viral infections; Fungal infections; Transplant recipients; Immune compromised persons